Clinuvel Pharmaceuticals Limited (CUV.AX)
Clinuvel Pharmaceuticals Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Melbourne, VIC, AU. The stock last traded at $9.56, up 0.63% on the session, giving a market capitalisation of $481.9M. Its beta of 0.57 implies it has historically moved less than the broad market.
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, the United States, Switzerland, and other global markets. The company's flagship drug, SCENESSE, serves as a systemic photoprotective treatment intended to prevent phototoxicity in adult patients diagnosed with erythropoietic protoporphyria (EPP). Clinuvel's development pipeline includes CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which promotes prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Additionally, Clinuvel Pharmaceuticals has partnered with HK Winhealth Pharma Group Co. Limited for a named patient program in the People's Republic of China, enabling the treatment of EPP patients with SCENESSE. Founded in 1987, the company's corporate headquarters are situated in Melbourne, Australia.
Clinuvel Pharmaceuticals Limited is most often compared with the following Healthcare names: